---
title: "Humacyte - CW27 | 10-Q: FY2025 Q1 Revenue: USD 517 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240063091.md"
datetime: "2025-05-13T21:13:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240063091.md)
  - [en](https://longbridge.com/en/news/240063091.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240063091.md)
generator: "portal-rs"
---

# Humacyte - CW27 | 10-Q: FY2025 Q1 Revenue: USD 517 K

Revenue: As of FY2025 Q1, the actual value is USD 517 K.

EPS: As of FY2025 Q1, the actual value is USD 0.28.

### Segment Revenue

-   **Product Revenue, Net**: $147,000 for the three months ended March 31, 2025.
-   **Contract Revenue**: $370,000 for the three months ended March 31, 2025.

### Operational Metrics

-   **Net Income**: $39,139,000 for the three months ended March 31, 2025, compared to a net loss of $31,896,000 for the same period in 2024.
-   **Loss from Operations**: - $23,184,000 for the three months ended March 31, 2025, compared to - $26,578,000 for the same period in 2024.
-   **Research and Development Expenses**: $15,418,000 for the three months ended March 31, 2025, a decrease from $21,264,000 for the same period in 2024.
-   **Selling, General and Administrative Expenses**: $8,136,000 for the three months ended March 31, 2025, an increase from $5,314,000 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $28,601,000 for the three months ended March 31, 2025, compared to - $27,347,000 for the same period in 2024.
-   **Net Cash Used in Investing Activities**: - $228,000 for the three months ended March 31, 2025, compared to - $391,000 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $46,739,000 for the three months ended March 31, 2025, compared to $62,795,000 for the same period in 2024.

### Unique Metrics

-   **Change in Fair Value of Contingent Earnout Liability**: $49,731,000 gain for the three months ended March 31, 2025, compared to a - $4,593,000 loss for the same period in 2024.
-   **Change in Fair Value of Derivatives**: $14,930,000 gain for the three months ended March 31, 2025, compared to a $60,000 gain for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to commercialize Symvess in the U.S. for vascular trauma and, if approved, in AV access for hemodialysis. It aims to obtain marketing approval for its 6 millimeter ATEV in additional indications and scale its manufacturing facility to meet market demand.
-   **Non-Core Business**: The company is exploring applications of its technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus, and other novel cell delivery systems.
-   **Priority**: The company estimates savings from workforce and other operating cost reductions, and reduced capital expenditures, totaling approximately $13.8 million in 2025 and up to approximately $38.0 million in 2026.

### Related Stocks

- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [Nvidia Just Delivered Bad News for AMD and Intel](https://longbridge.com/en/news/297432140.md)
- [Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?](https://longbridge.com/en/news/297409652.md)
- [Frontline Earnings Call: Record Profits Amid Mounting Risks](https://longbridge.com/en/news/297410743.md)
- [Caisse de depot et placement du Quebec Takes $8.90 Million Position in Albemarle Corporation $ALB](https://longbridge.com/en/news/297418340.md)
- [Equitable Holdings Inc. Takes Position in TechnipFMC plc $FTI](https://longbridge.com/en/news/297418121.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**